U.S., July 10 -- ClinicalTrials.gov registry received information related to the study (NCT07057310) titled 'Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women' on May 05.
Brief Summary: In postmenopausal women, obesity increases the risk of physical function decline, premature aging, and vascular dysfunction. Semaglutide and tirzepatide are potent obesity medications. The goal is to determine the effect of weight loss induced by the new generation of GLP-1 receptor agonists on physical function, aging biomarkers, and vascular function in postmenopausal women with obesity.
Study Start Date: May 01
Study Type: INTERVENTIONAL
Condition:
Obesity
Menopause
Intervention:
DRUG:...